{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:51:00Z","timestamp":1790841060208,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01084-8","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T17:10:06Z","timestamp":1614100206000},"page":"1057-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["LY3022855, an anti\u2013colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial"],"prefix":"10.1007","volume":"39","author":[{"given":"Afshin","family":"Dowlati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Sae Wook","family":"Kauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya C.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Szpurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Quinlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-0648","authenticated-orcid":false,"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"issue":"5","key":"1084_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"1084_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fcell.2018.00038","volume":"6","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Kitamura T (2018) Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front Cell Dev Biol 6:38. https:\/\/doi.org\/10.3389\/fcell.2018.00038","journal-title":"Front Cell Dev Biol"},{"issue":"19","key":"1084_CR3","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1158\/1078-0432.CCR-16-3261","volume":"23","author":"KP Papadopoulos","year":"2017","unstructured":"Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr (2017) First-in-human study of AMG 820, a monoclonal anti-Colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin Cancer Res 23(19):5703\u20135710. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3261","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1084_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5(1):53. https:\/\/doi.org\/10.1186\/s40425-017-0257-y","journal-title":"J Immunother Cancer"},{"issue":"5877","key":"1084_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.1154370","volume":"320","author":"H Lin","year":"2008","unstructured":"Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320(5877):807\u2013811. https:\/\/doi.org\/10.1126\/science.1154370","journal-title":"Science"},{"issue":"11","key":"1084_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tcb.2004.09.016","volume":"14","author":"FJ Pixley","year":"2004","unstructured":"Pixley FJ, Stanley ER (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14(11):628\u2013638. https:\/\/doi.org\/10.1016\/j.tcb.2004.09.016","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1084_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1(1):54\u201367. https:\/\/doi.org\/10.1158\/2159-8274.CD-10-0028","journal-title":"Cancer Discov"},{"issue":"3","key":"1084_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2249.2010.04200.x","volume":"161","author":"C Subimerb","year":"2010","unstructured":"Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, Wongkham S (2010) Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol 161(3):471\u2013479. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04200.x","journal-title":"Clin Exp Immunol"},{"issue":"18","key":"1084_CR9","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG (2014) CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057\u20135069. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3723","journal-title":"Cancer Res"},{"key":"1084_CR10","unstructured":"ClinicalTrials.Gov. A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers. Available on https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01316822. Accessed on 5 May 2020"},{"key":"1084_CR11","unstructured":"ClinicalTrials.gov. Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors. Available on https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01804530. Accessed on April 4 2020"},{"key":"1084_CR12","unstructured":"ClinicalTrials.gov. Phase I\/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors. Available on https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02829723. Accessed on April 4 2020"},{"issue":"8","key":"1084_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","volume":"30","author":"CA Gomez-Roca","year":"2019","unstructured":"Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Ruttinger D, Delord JP, Blay JY (2019) Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol 30(8):1381\u20131392. https:\/\/doi.org\/10.1093\/annonc\/mdz163","journal-title":"Ann Oncol"},{"key":"1084_CR14","unstructured":"ClinicalTrials.gov. A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread. Available on https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03158272. Accessed on April 4 2020"},{"key":"1084_CR15","unstructured":"ClinicalTrials.gov. Phase Ib\/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies. Available on https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02807844. Accessed on April 4 2020"},{"key":"1084_CR16","unstructured":"Insight A IMC.CS4. Available on https:\/\/adisinsight.springer.com\/drugs\/800034411. Accessed 5 May 2020"},{"issue":"2","key":"1084_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1084_CR18","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available on https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accesssed 16 mar 2020"},{"key":"1084_CR19","unstructured":"United States Food and Drug Administration. Immunogenicity Assessment for Therapeutic Protein Products. Available at https:\/\/www.fda.gov\/media\/85017\/download. Accessed on October 1 2020"},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2017.35.15_suppl.2523","volume":"35","author":"A Dowlati","year":"2017","unstructured":"Dowlati A, Rugo H, Harvey D, Kudchadkar R, Carvajal R, Manji G, Hamid O, Klempner S, Tang S, Yu D, Kauh J, Schaer D, Tate S, Wesolowski R (2017) A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 35:2523. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.2523","journal-title":"J Clin Oncol"},{"key":"1084_CR21","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.2019.37.15_suppl.2548","volume":"37","author":"K Autio","year":"2019","unstructured":"Autio K, Klebanoff C, Schaer D, Kauh J, Slovin S, Blinder V, Comen E, Danila D, Hoffman D, Kang S, McAndrew P, Modi S, Morris M, Rathkopf D, Sanford R, Tate S, Yu D, McArthur H (2019) Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC). J Clin Oncol 37:2548. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2548","journal-title":"J Clin Oncol"},{"issue":"1","key":"1084_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","volume":"38","author":"JH Lee","year":"2020","unstructured":"Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC (2020) A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Investig New Drugs 38(1):99\u2013110. https:\/\/doi.org\/10.1007\/s10637-019-00745-z","journal-title":"Investig New Drugs"},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"175883591985423","DOI":"10.1177\/1758835919854238","volume":"11","author":"R Wesolowski","year":"2019","unstructured":"Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS (2019) Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol 11:1758835919854238. https:\/\/doi.org\/10.1177\/1758835919854238","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"1084_CR24","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","volume":"21","author":"B von Tresckow","year":"2015","unstructured":"von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A (2015) An open-label, multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Clin Cancer Res 21(8):1843\u20131850. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1845","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1084_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","volume":"11","author":"M Ovacik","year":"2018","unstructured":"Ovacik M, Lin K (2018) Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci 11(6):540\u2013552. https:\/\/doi.org\/10.1111\/cts.12567","journal-title":"Clin Transl Sci"},{"issue":"10","key":"1084_CR26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"J Hendrikx","year":"2017","unstructured":"Hendrikx J, Haanen J, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH (2017) Fixed dosing of monoclonal antibodies in oncology. Oncologist 22(10):1212\u20131221. https:\/\/doi.org\/10.1634\/theoncologist.2017-0167","journal-title":"Oncologist"},{"issue":"2","key":"1084_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/11596370-000000000-00000","volume":"51","author":"S Bai","year":"2012","unstructured":"Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ (2012) A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 51(2):119\u2013135. https:\/\/doi.org\/10.2165\/11596370-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1084_CR28","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Ruttinger D (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6):846\u2013859. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.016","journal-title":"Cancer Cell"},{"issue":"12","key":"1084_CR29","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/1535-7163.MCT-16-0157","volume":"15","author":"LP Pradel","year":"2016","unstructured":"Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Ruttinger D, Ries CH (2016) Macrophage susceptibility to Emactuzumab (RG7155) treatment. Mol Cancer Ther 15(12):3077\u20133086. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0157","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1084_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059771","volume":"8","author":"LQ Kong","year":"2013","unstructured":"Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC (2013) The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One 8(3):e59771. https:\/\/doi.org\/10.1371\/journal.pone.0059771","journal-title":"PLoS One"},{"key":"1084_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek C, Ponten F, Jirstrom K, Leandersson K (2012) The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12:306. https:\/\/doi.org\/10.1186\/1471-2407-12-306","journal-title":"BMC Cancer"},{"issue":"5","key":"1084_CR32","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.3892\/etm.2018.5959","volume":"15","author":"K Minami","year":"2018","unstructured":"Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S (2018) Prognostic significance of CD68, CD163 and Folate receptor-beta positive macrophages in hepatocellular carcinoma. Exp Ther Med 15(5):4465\u20134476. https:\/\/doi.org\/10.3892\/etm.2018.5959","journal-title":"Exp Ther Med"},{"issue":"19","key":"1084_CR33","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.7150\/jca.33914","volume":"10","author":"C Ni","year":"2019","unstructured":"Ni C, Yang L, Xu Q, Yuan H, Wang W, Xia W, Gong D, Zhang W, Yu K (2019) CD68- and CD163-positive tumor infiltrating macrophages in non-metastatic breast cancer: a retrospective study and meta-analysis. J Cancer 10(19):4463\u20134472. https:\/\/doi.org\/10.7150\/jca.33914","journal-title":"J Cancer"},{"key":"1084_CR34","doi-asserted-by":"publisher","unstructured":"Gyori D, Lim EL, Grant FM, Spensberger D, Roychoudhuri R, Shuttleworth SJ, Okkenhaug K, Stephens LR, Hawkins PT (2018) Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight 3(11). https:\/\/doi.org\/10.1172\/jci.insight.120631","DOI":"10.1172\/jci.insight.120631"},{"issue":"5","key":"1084_CR35","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Pure E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI (2017) Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32(5):654\u2013668 e655. https:\/\/doi.org\/10.1016\/j.ccell.2017.10.005","journal-title":"Cancer Cell"},{"issue":"3","key":"1084_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s10637-012-9894-7","volume":"31","author":"A McKane","year":"2013","unstructured":"McKane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ (2013) Determinants of patient screen failures in phase 1 clinical trials. Investig New Drugs 31(3):774\u2013779. https:\/\/doi.org\/10.1007\/s10637-012-9894-7","journal-title":"Investig New Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01084-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:09Z","timestamp":1678511229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01084-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01084-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"8 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the International Conference on Harmonization guidelines and Declaration of Helsinki 1964 and its amendments. The Institutional review board of each study site approved the study protocol, information brochure and the informed consent form before study initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients provided informed consent to regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<b>A. Dowlati<\/b> reports other from Glaxo Smith Kline, non-financial support from Glaxo Smith Kline; grants from EMD Serono, Tesaro, Roche, Vertex, Regeneron; grants and personal fees from Abbvie, Astra Zeneca, Millenium, Seattle Genetics; grants from Eli Lilly, Takeda, Ipsen, United Therapeutics, Mirati, Bristol Myers Squibb, Incuron; personal fees from Ariad, grants from Bayer.<b>RD. Harvey<\/b> has nothing to disclose.<b>R. Carvajal<\/b> reports personal fees and other from BMS, Incyte, Immunocore, Merck Roche\/Genentech; personal fees from Castle Biosciences, Compugen, Foundation Medicine, I-Mab, PureTech, Sanofi Genzyme, Sorrento Therapeutics, Aura Biosciences, Chimeron, Rgenix; other from Amgen, Novartis, Pfizer, AstraZeneca, Bellicum, Plexxikon, Mirati, Macrogenics, Corvus, Bayer, Eli Lilly, Astellis, outside the submitted work.<b>O. Hamid<\/b> received personal fees from Aduro, Akeso, Amgen, Array, Beigene, BMS, Genentech, GSK, Immunocore, Incyte, Janssen, Merck, Nextcure, Novartis, Sanofi Regeneron, Seattle Genetics, Tempus, Zelluna, Array Pfizer, BMS, Novartis, Sanofi Regeneron; other from Arcus, Aduro, Akeso, Amgen, Array, BMS, CytomX, Exelixis, Genentech, GSK, Immunocore, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Sanofi Regeneron, Seattle Genetics, Torque, Zelluna.<b>SJ. Klempner<\/b> received personal fees from Eli Lilly, Merck, Bristol Myers Squibb, Foundation Medicine, Inc., Pieris; Stock\/equity from Turning Point Therapeutics.<b>JSW. Kauh<\/b> is a former employee of Eli Lilly and Company and presently working at Hutchison MediPharma Inc.<b>R. Wesolowski<\/b> reports other (Lilly covered the cost of conducting this study at our institution).<b>AM. Szpurka, DA. Peterson, D. Yu, M. Carlsen, SC. Chapman, and T. Quinlan,<\/b> are employees and stockholder at Eli Lilly and Company.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}